The purpose of the study is to evaluate the outcome of treatment switch defined as an improvement in CGI-CB scale (Clinical Global Impression - Clinical Benefit).

Inclusion Criteria:

• Diagnosis of schizophrenia (as per DSM-IV), at least 6 months prior to enrolment in the study
• Subjects who have initiated a new antipsychotic treatment within the preceding 2 weeks
• Subjects whose prior and current antipsychotic treatment consists of any typical or atypical antipsychotic monotherapy

Exclusion Criteria:

• Subjects fulfilling criteria for diagnosis of any other psychiatric condition (except from schizophrenia), as per DSM-IV Axis Ι, concomitant organic mental disorder or mental retardation
• Substance abuse or dependence (with the exception of nicotine dependence), as defined by DSM-IV criteria and not in full remission
• Female subjects who are pregnant or lactating

Subjects who have undergone a switch in their antipsychotic treatment and fulfill the following criteria will participate in the study.